DiaMedica Therapeutics, Inc. (DMAC)
8.79
-0.54
(-5.79%)
USD |
NASDAQ |
Nov 13, 16:00
8.79
0.00 (0.00%)
After-Hours: 19:59
DiaMedica Therapeutics Enterprise Value : 459.81M for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 459.81M |
| November 11, 2026 | 477.60M |
| November 10, 2026 | 478.14M |
| November 09, 2026 | 477.06M |
| November 06, 2026 | 461.43M |
| November 05, 2026 | 444.17M |
| November 04, 2026 | 537.46M |
| November 03, 2026 | 495.94M |
| November 02, 2026 | 457.65M |
| October 30, 2026 | 455.49M |
| October 29, 2026 | 470.05M |
| October 28, 2026 | 486.23M |
| October 27, 2026 | 425.30M |
| October 26, 2026 | 427.99M |
| October 23, 2026 | 426.91M |
| October 22, 2026 | 422.06M |
| October 21, 2026 | 425.30M |
| October 20, 2026 | 424.22M |
| October 19, 2026 | 381.08M |
| October 16, 2026 | 364.90M |
| October 15, 2026 | 390.24M |
| October 14, 2026 | 369.75M |
| October 13, 2026 | 378.38M |
| October 12, 2026 | 398.87M |
| October 09, 2026 | 405.88M |
| Date | Value |
|---|---|
| October 08, 2026 | 388.63M |
| October 07, 2026 | 387.55M |
| October 06, 2026 | 395.10M |
| October 05, 2026 | 410.74M |
| October 02, 2026 | 400.49M |
| October 01, 2026 | 406.96M |
| September 30, 2026 | 402.65M |
| September 29, 2026 | 398.87M |
| September 28, 2026 | 405.34M |
| September 25, 2026 | 384.85M |
| September 24, 2026 | 378.92M |
| September 23, 2026 | 364.36M |
| September 22, 2026 | 376.22M |
| September 21, 2026 | 348.18M |
| September 18, 2026 | 326.07M |
| September 17, 2026 | 326.07M |
| September 16, 2026 | 314.21M |
| September 15, 2026 | 308.82M |
| September 14, 2026 | 309.89M |
| September 11, 2026 | 305.58M |
| September 10, 2026 | 305.58M |
| September 09, 2026 | 312.05M |
| September 08, 2026 | 309.36M |
| September 04, 2026 | 320.68M |
| September 03, 2026 | 310.43M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 6.429B |
| Nektar Therapeutics | 722.92M |
| Fortress Biotech, Inc. | -35.02M |
| ACADIA Pharmaceuticals, Inc. | 2.230B |
| Alnylam Pharmaceuticals, Inc. | 20.38B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -10.14M |
| Total Expenses (Quarterly) | 10.14M |
| EPS Diluted (Quarterly) | -0.1881 |
| Earnings Yield | -8.12% |
| Normalized Earnings Yield | -8.123 |